An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge

Palin, Amy; Chattopadhyay, Anasuya; Park, Steven; Delmas, Guillaume; Suresh, Rema; Senina, Svetlana; Perlin, David S.; Rose, John K.

doi:10.1016/j.vaccine.2006.08.010

Cited by 34 publications

(39 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current efforts have centered on the development of subunit vaccines using Y. pestis F1 and LcrV antigens. Plague vaccines based on DNA, bacterial or viral vectors have also been shown to be effective in animal models [14, 30, 48, 49]. Recently, a VACV that expressed F1-LcrV fusion protein was shown to elicit protection of mice against intranasal challenge of 10 × LD50 of an attenuated Y. pestis strain [50].…”

Section: Discussionmentioning

confidence: 99%

Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion

Embry¹,

Meng²,

Cantwell³

et al. 2011

Vaccine

View full text Add to dashboard Cite

Vaccinia virus (VACV) is the vaccine for smallpox and a widely-used vaccine vector for infectious diseases and cancers. The majority of the antibodies elicited by live VACV vaccination respond to virion structural proteins, including many integral membrane proteins on the intracellular mature virion (MV). Here, we showed that antibody response to an exogenous antigen delivered by VACV was greatly enhanced by incorporating the antigen as an integral membrane protein of MV. We constructed recombinant VACV expressing a Y. pestis protective antigen, LcrV, unmodified or fused with either a signal peptide or with the transmembrane domain of VACV D8 protein (LcrV-TM). Electron microscopy showed that LcrV-TM was displayed on the surface of MV. Importantly, VACV expressing LcrV-TM elicited a significantly higher titer of anti-LcrV antibody in mice than viruses expressing other forms of LcrV. Only mice immunized with LcrV-TM-expressing VACV were protected from lethal Y. pestis and VACV WR challenges. Antigen engineering through fusion with D8 transmembrane domain may be broadly applicable for enhancing the immune response to antigens delivered by a VACV vector. The recombinant virus described here could also serve as the basis for developing a vaccine against both smallpox and plague.

show abstract

Section: Discussionmentioning

confidence: 99%

Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion

Embry¹,

Meng²,

Cantwell³

et al. 2011

Vaccine

View full text Add to dashboard Cite

show abstract

“…A single oral dose of attenuated salmonella expressing F1 and/or LcrV protects mice against subcutaneous [102][103][104][105] and intranasal challenge [106]. An intranasal prime-boost regimen with vesicular stomatitis virus expressing LcrV protects mice against intranasal challenge [107], and a single intramuscular vaccination with adenovirus expressing LcrV protects mice against intranasal challenge for at least 6 months [108].…”

Section: Recent Advances In Plague Vaccine Designmentioning

confidence: 99%

Current challenges in the development of vaccines for pneumonic plague

Smiley¹

2008

Expert Review of Vaccines

141

197

View full text Add to dashboard Cite

Inhalation of Yersinia pestis bacilli causes pneumonic plague, a rapidly progressing and exceptionally virulent disease. Extensively antibiotic-resistant Y. pestis strains exist and we currently lack a safe and effective pneumonic plague vaccine. These facts raise concern that Y. pestis may be exploited as a bioweapon. Here, I review the history and status of plague vaccine research and advocate that pneumonic plague vaccines should strive to prime both humoral and cellular immunity.

show abstract

“…Anti-V antibodies administered to infected mice restored the production of TNF-α and IFN-γ and shown to block partially the delivery of Yops into macrophages [20]. Newer vaccines that induce long lived immunity against bubonic and pneumonic plague however may need to be developed [21].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of CD4+/CD8+ T-cell expression and IFN-γ, perforin secretion for B–T constructs of F1 and V antigens of Yersinia pestis

Gupta

Ali

Khan

et al. 2012

International Immunopharmacology

View full text Add to dashboard Cite

An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge

Cited by 34 publications

References 62 publications

Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion

Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion

Current challenges in the development of vaccines for pneumonic plague

Evaluation of CD4+/CD8+ T-cell expression and IFN-γ, perforin secretion for B–T constructs of F1 and V antigens of Yersinia pestis

Contact Info

Product

Resources

About